TABLE 1

Patient Demographics and Characteristics

CharacteristicDetailsTotalCRLRDR
Mean age (y)58 (39–77)59 (39–77)58 (46–74)59 (40–76)
SexMale31 (79)7 (64)15 (88)9 (81)
Female8 (21)4 (36)2 (12)2 (18)
HistologySCC21 (54)2 (18)14 (82)5 (45)
ADC10 (26)5 (45)1 (6)4 (36)
LCUC8 (20)4 (36)2 (12)2 (18)
TNM stageIIa3 (8)1 (9)11 (6)1 (9)
IIb2 (5)1 (9)1 (6)0
IIIa15 (38)4 (36)8 (47)3 (27)
IIIb19 (49)5 (45)7 (41)7 (64)
Location of tumorRSL19 (39)5 (45)6 (35)8 (73)
RML3 (8)1 (9)2 (12)0
RIL3 (8)2 (18)1 (6)0
LSL11 (28)3 (27)6 (35)2 (18)
LIL4 (10)03 (18)1 (9)
Induction chemotherapyYes33 (85)9 (81)13 (76)10 (91)
No6 (15)2 (18)4 (24)1 (9)
Dose (Gy)At PETC44 (40–52)45 (42–50)45 (40–52)43 (40–46)
Total67 (60–70)66 (60–70)67 (60–70)68 (66–70)
Time of follow-up (mo)30 (6–76)46 (18–76)22 (6–60)27 (11–51)
RT duration (d)48 (39–66)47 (41–53)48 (39–66)48 (45–52)
SUVmaxPETA11.0 (3.7–22.1)11.7 (5.5–18.1)11.7 (3.7–22.1)10.9 (5.1–16.6)
PETB8.4 (1.2–20.8)7.5 (1.2–15.2)9.1 (2.5–18.9)8.4 (2.8–20.8)
PETC5.6 (0.8–13.1)4 (0.8–5.9)6.8 (2.3–11.9)5.2 (1.1–3.15)
MTV (cm3)PETA (A40)54.0 (2.4–176.3)44.8 (6.6–125.8)63.8 (10.6–176.3)47.0 (2.4–103.2)
PETB (B40)26.2 (1.7–86.6)18.2 (0.7–31.2)32.4 (9.2–86.6)24.8 (1.5–73.4)
PETC (C40)30.9 (0.8–77.8)28.6 (0.8–77.6)34 (4.2–76.2)5.2 (2.9–57.8)
  • SCC = squamous cell carcinoma; ADC = adenocarcinoma; LCUC = large cell undifferentiated carcinoma; RSL = right superior lobe; RML = right median lobe; RIL = right inferior lobe; LSL = left superior lobe; LIL: = left inferior lobe; RT = radiotherapy; MTV = metabolic tumor volume.

  • Data in parentheses are percentages or ranges.